The invention of auto-injectors is a boon to the patients who suffer from allergies. There is a strong rise in development of affordable generic models. This could increase the availability of low cost auto injectors around the world.
Browse full research report @ http://www.radiantinsights.com/research/emea-europe-middle-east-and-africa-auto-injectors-industry-2017
What are Auto-Injectors?
Auto-injectors are the pen-like medical devices used to treat anaphylactic shock. These devices find applications for the treatment of diabetes, Rheumatoid Arthritis (RA), and Multiple Sclerosis (MS). Disposable and reusable are the two major types of auto-injectors. These devices have a built-in safety mechanism to prevent needlestick injuries. This preventive measure has been implemented to deter drug addicts. Surge in allergy attacks among school going kids has led to their mandatory presence on school campuses. Its transition in delivery route from subcutaneous to intradermal points can lead to rapid drug delivery.
The drastic surge in prices of Mylan’s Epi-Pen led to the launch of generic auto-injectors. These affordable devices provided a big relief to the people dependent on them. Companies such as Cigna and CVS Health have decided to capture the manufacturing gap by launching enhanced versions of their existing products at economical rates.
Development of biologic therapies to treat immediate pain and provide relief has been possible with the help of auto-injectors. The European Commission allowed the use of sarilumab in combination with methotrexate to treat RA patients. This drug can be administered with disposable syringes for patients who are unresponsive to other drugs.
Wearable injectors are a booming trend within the industry which has promising potential. They can be used to dispense large volumes of drugs that are deemed incompatible with disposable or reusable injectors. Although in its developmental stage, its use can extend to treating cardiovascular, neurological, and autoimmune diseases.
The auto-injectors market in the EMEA region is expected to attain high revenue by 2022, according to a report available on Radiant Insights, Inc. It is driven by rising cases of multiple sclerosis, rheumatoid arthritis, and anaphylaxis. The market is expected to exhibit a significant CAGR during the forecast period (from 2012 to 2022). High demand for auto-injectors to provide relief from anaphylactic shock can further support the expansion.
Reusable auto-injectors are used to deliver growth hormones, while disposable auto-injectors can deliver biologic drugs for chronic diseases. Clinics, hospitals, and others are the major application areas. Immense demand from hospitals can impel market over the forecast period. Clinics offer educational courses to enlighten first-time users. Notable market players are Ypsomed Holding AG; Mylan, Inc.; Becton, Dickinson and Company (BD); and Sanofi S.A.
Request free sample at: